Targeting Gal-1 for aneurysm prevention may require the selective inhibition of its inflammatory and matrix-degrading properties, whereas interventions for CAD and heart failure should focus on modulating its fibrotic activity. Here, LGALS1 is linked to coronary artery disorder.